Welcome to our dedicated page for Cidara Theraptcs news (Ticker: CDTX), a resource for investors and traders seeking the latest updates and insights on Cidara Theraptcs stock.
Cidara Therapeutics, Inc. (CDTX), headquartered in San Diego, California, is a pioneering biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives and immunotherapies. The company's mission is to address diseases inadequately treated by current standard of care therapies. Utilizing its proprietary Cloudbreak® platform, Cidara develops drug-Fc conjugates (DFCs) aimed at saving lives and improving patient outcomes for serious diseases such as cancer, viral infections, and autoimmune diseases.
The company's core portfolio includes:
- Rezafungin (REZZAYO™): An FDA and EC-approved treatment for invasive candidiasis, licensed to multiple partners for commercialization in the U.S. and internationally.
- CD101 IV: A potential once-weekly intravenous therapy for systemic fungal infections.
- CD101 Topical: The first topical application of the echinocandin class of anti-fungals for vulvovaginal candidiasis (VVC).
- CD388: A long-acting antiviral investigational drug for the prevention of all strains of influenza A and B, currently in Phase 2b development.
Recent achievements include significant data presentations at prestigious conferences and strategic realignments to focus on the most promising components of their pipeline. Cidara’s financial stability is reinforced by a $240 million private placement led by RA Capital Management, with participation from top-tier investors like Bain Capital Life Sciences and Biotech Value Fund (BVF).
Noteworthy partnerships include collaborations with Johnson & Johnson for CD388 and Mundipharma for the divestiture of rezafungin, which has led to substantial cost savings and allows Cidara to focus on its Cloudbreak platform. The company is also preparing for a Phase 2b clinical trial of CD388, aiming to deliver universal, season-long protection against influenza.
For more information, visit www.cidara.com.
Cidara Therapeutics (Nasdaq: CDTX) announced its participation in the 21st International Immunocompromised Host Society Symposium, occurring virtually from Feb. 17-19, 2021. The company will present significant findings on rezafungin, its novel once-weekly echinocandin currently in Phase 3 trials for treating serious fungal infections. Key presentations include an oral overview by Dr. Taylor Sandison and three poster presentations focused on rezafungin's efficacy. Additionally, Cidara will showcase preclinical data on its antiviral conjugate candidate, CD377, targeting influenza.
Cidara Therapeutics (Nasdaq: CDTX) announced the addition of Bonnie Bassler, Ph.D., and Carin Canale-Theakston to its board of directors. Dr. Bassler brings extensive molecular biology expertise and experience from various biotech boards, while Canale-Theakston boasts over 25 years in life sciences communications. Their appointments aim to bolster the company's focus on advancing its antifungal candidate, rezafungin, which is currently in Phase 3 trials, and its antiviral conjugate programs targeting influenza.
Cidara Therapeutics (Nasdaq: CDTX) has granted a stock option for 115,000 shares to a new employee under its 2020 Inducement Incentive Plan, effective December 31, 2020. The exercise price is $2.00 per share, equal to the closing price on the grant date. The option vests over four years, with 25% vesting after one year and the remainder in monthly installments. This award complies with Nasdaq Listing Rule 5635(c)(4) as an inducement for the employee's hiring. Cidara focuses on long-acting therapeutics for serious fungal and viral infections, including its lead candidate, rezafungin.
Cidara Therapeutics, Inc. (Nasdaq: CDTX) has appointed Christopher Kurtz as executive vice president of technical operations to advance its antifungal and antiviral programs. With over 26 years of experience, Kurtz's expertise in manufacturing and supply chain management is expected to drive the company's ongoing Phase 3 trials of rezafungin, aimed at treating serious fungal infections. The company also seeks to leverage its Cloudbreak platform for developing long-acting antiviral conjugates against various viruses. The leadership change is viewed as a pivotal step for Cidara's growth and product development.
Cidara Therapeutics (Nasdaq: CDTX) announced its participation in the 7th European Scientific Working Group on Influenza (ESWI) Conference, scheduled for Dec. 6-9, 2020. Highlights include a keynote lecture on the innovative Cloudbreak antiviral platform aimed at universal influenza protection, delivered by Les Tari, Ph.D., on Dec. 7. Additionally, presentations will feature preclinical data on the antiviral conjugate CD377, focusing on its efficacy against various influenza strains, including HPAI and Oseltamivir-resistant isolates. These findings promise advancements in preventing and treating influenza.
Cidara Therapeutics (Nasdaq: CDTX) announced plans to present three posters at the ESICM LIVES 2020 virtual conference from December 6-9, 2020. The presentations will focus on findings from the Phase 2 STRIVE trial of rezafungin for treating candidemia and invasive candidiasis. Key analyses include ICU status, geographic enrollment, and body mass index outcomes compared to caspofungin. Rezafungin is currently undergoing pivotal Phase 3 trials. For further details, copies of the posters will be available on Cidara's website.
Cidara Therapeutics (Nasdaq: CDTX) announced that its CEO, Jeffrey Stein, Ph.D., will participate in two upcoming virtual conferences. The first is the Stifel 2020 Virtual Healthcare Conference, scheduled for November 17, 2020, at 2:00 PM ET. The second event is the 3rd Annual Evercore ISI HealthCONx Conference on December 2, 2020, at 11:20 AM ET, featuring a panel discussion focused on fungal needs. Cidara specializes in developing long-acting therapeutics for fungal and viral infections, including its lead antifungal candidate, rezafungin.
Cidara Therapeutics, Inc. (Nasdaq: CDTX) reported Q3 2020 financial results, highlighting a net loss of $17.6 million, compared to a net income of $3.0 million in Q3 2019. Revenue totaled $2.4 million for the quarter, significantly down from $19.1 million in the same period last year, largely due to a previous intellectual property licensing deal. Research and development expenses increased to $16.3 million, reflecting higher costs related to rezafungin trials. Cidara continues to advance rezafungin through Phase 3, targeting top-line data by late 2021 amid COVID-19 challenges.
Cidara Therapeutics (Nasdaq: CDTX) presented significant clinical data at IDWeek 2020, highlighting its antifungal candidate, rezafungin, for treating candidemia and invasive candidiasis. Analyses from the completed Phase 2 STRIVE trial demonstrated rezafungin's robust efficacy against multiple Candida species across diverse patient populations. Additionally, data on the Cloudbreak antiviral platform showcased the promising antiviral candidate, CD377, which demonstrated strong protective effects against influenza.
FAQ
What is the current stock price of Cidara Theraptcs (CDTX)?
What is the market cap of Cidara Theraptcs (CDTX)?
What is Cidara Therapeutics' primary focus?
What is the Cloudbreak® platform?
What are some of Cidara's key products?
Has Cidara received any approvals for its products?
What recent strategic decisions has Cidara made?
How is Cidara funded?
What upcoming clinical trials does Cidara have?
Where is Cidara Therapeutics headquartered?
Who are Cidara's major partners?
How can I get more information about Cidara?
